Bernard Flourié

Bernard Flourié

Auto-generated profile, based on publicly available information

Bernard Flourié

Department of Gastroenterology, University Hospital of Lyon, France

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
YBYoram Bouhnik
Yoram Bouhnik
LRLaurent Raskine
Laurent Raskine
GSGuy Simoneau
Guy Simoneau
EVEric Vicaut
Eric Vicaut
CNChristel Neut
Christel Neut
FBFrancis R Bornet
Francis R Bornet
Background: Nondigestible carbohydrates (NDCHs) are fermented in the colon, where they can selectively promote the growth of bifidobacteria. Objective: Our aim was to determine the bifidogenic potential of different NDCHs used in human diets. Design: Two hundred healthy volunteers participated in this double-blind study. During phase 1 (screening), 64 volunteers were randomly assigned to 8 groups of 8 subjects each; for 7 d, they ingested 10 g/d of 1 of the 7 NDCHs tested or of the placebo. During phase 2 (dose-response study), 136 volunteers were randomly assigned to 4 groups of 32 subjects who received 2.5, 5.0, 7.5, or 10 g/d, respectively (8 subjects/dose), of one of the NDCHs that were proven to be bifidogenic during phase 1 and a fifth group of 8 subjects (control subjects) who received the placebo. Stools were recovered before and after NDCH consumption. Results: In phase 1, 4 NDCHs were found to be bifidogenic: short-chain fructooligosaccharides (P = 0.008), soybean oligosaccharides (P = 0.006), galactooligosaccharides (P < 0.0001), and type III resistant starch (P = 0.02); lactulose, long-chain inulin, and isomaltooligosaccharides were not bifidogenic. In phase 2, the effects of 7-d treatment on bifidobacteria concentrations were found to differ significantly among the 4 NDCHs (P = 0.009 for time × treatment interaction). However, no significant differences were found among doses, and there was no significant dose × time interaction. A low baseline bifidobacteria count was significantly associated with the bifidogenic response to treatment (P < 0.001). Conclusion: This study showed the different bifidogenic properties among the substrates and underlined the importance of taking into account the baseline bifidobacteria counts when evaluating the effect of the treatment.

1 January 1999 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
YBYoram Bouhnik
Yoram Bouhnik
KVKouroche Vahedi
Kouroche Vahedi
LALotfi ACHOUR
Lotfi ACHOUR
AAAlain Attar
Alain Attar
JSJérôme Salfati
Jérôme Salfati
JRJean-Claude Rambaud
Jean-Claude Rambaud
Short-chain fructo-oligosaccharides (SC-FOS) are a mixture of oligosaccharides consisting of glucose linked to fructose units (Gfn; n = ≤ 4), which are not digested in the human small intestine but are fermented in the colon where they specifically promote the growth of bifidobacteria. In healthy volunteers, we assessed the tolerance and the threshold dose of SC-FOS that significantly increased fecal bifidobacteria counts and the possibility of a dose-response relationship. Randomly divided into five groups and eating their usual diets, healthy volunteers (40: 18 males, 22 females) ingested in two oral doses for 7 d a powder mixture containing (g SC-FOS/d): 0, G0; 2.5, G2.5; 5, G5; 10, G10; 20, G20. Stools were collected before (d1) and at the end (d8) of sugar consumption, and tolerance was evaluated using a daily chart. Total anaerobe counts were not affected by SC-FOS ingestion. Bifidobacteria counts at d8 were greater in groups G10 and G20 than in G0 and G2.5 (P < 0.05). Fecal pH did not differ among groups. A significant correlation between the dose of SC-FOS ingested and the fecal bifidobacteria counts was observed at d8 (r = 0.53; P < 0.01). Excess flatus was significantly more frequent in subjects consuming G20 than in those consuming G0, G2.5 or G5 (P < 0.05), and more intense in G20 than in G0 and G5 groups (P < 0.05). In conclusion, the optimal and well-tolerated dose of SC-FOS that significantly increased fecal bifidobacteria in healthy volunteers consuming their usual diet is 10 g/d.

1 March 1997 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
YBYoram Bouhnik
Yoram Bouhnik
BFBernard Flourié
Bernard Flourié
LDLaurence D'Agay-Abensour
Laurence D'Agay-Abensour
PPPhilippe Pochart
Philippe Pochart
GGGeneviève Gramet
Geneviève Gramet
JRJean-Claude Rambaud
Jean-Claude Rambaud
Transgalacto-oligosaccharides are a mixture of oligosaccharides consisting of glucose and galactose; they are not digested in the human small intestine. In vitro, they specifically stimulate the growth of bifidobacteria. The aim of the present work was to assess tolerance of transgalacto-oligosaccharides and the effects of their prolonged administration on bifidobacteria and fermentative activity of colonic flora. Eight healthy subjects were given 10 g of transgalacto-oligosaccharides per day for 21 d in two daily doses. A breath test and stool sample collection were carried out on d 1, 7, 14 and 21 of transgalacto-oligosaccharides ingestion. The stools of three subjects were collected and mixed before the study, and then inoculated in vitro into a fermentor to which 10 g transgalacto-oligosaccharides was added daily for 14 d. In the eight volunteers, administration of transgalacto-oligosaccharides led to a significant decrease in breath hydrogen excretion (P < 0.01) and a significant increase in fecal concentrations of bifidobacteria from (means ± SEM) 8.6 ± 0.6 to 9.7 ± 0.5, 9.7 ± 0.6 and 9.5 ± 0.6 log colony-forming units (CFU)/g on d 1, 7, 14 and 21, respectively (P < 0.05). Fecal concentrations of enterobacteria, as well as stool weight, fecal water and pH did not change during the study. In vitro, transgalacto-oligosaccharides fermentation became more efficient and faster with time. In addition, metabolic alterations such as a rise in acetate proportion and lactate formation after 7 d of fermentation were observed, indicating the transformation of the inoculated fecal flora into an acid-resistant lactic flora. Prolonged administration of transgalacto-oligosaccharides, at a dose which does not induce digestive symptoms, increases the number of bifidobacteria and alters the fermentative activity of colonic flora in humans.

1 February 1985 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CFC Florent
C Florent
BFB Flourie
B Flourie
ALA Leblond
A Leblond
MRM Rautureau
M Rautureau
JBJ J Bernier
J J Bernier
JRJ C Rambaud
J C Rambaud
The effects of a chronic load of nonabsorbable sugars on intracolonic bacterial metabolism of carbohydrates and on H2 breath excretion are disputed. However, most of the discussion relies on indirect evidence or on results of in vitro studies. Thus, we attempted to assess directly and in vivo the effects on intracolonic metabolism of lactulose of a chronic oral load of this nonabsorbable disaccharide. 20 g of lactulose was given orally twice daily during 8 d to eight normal volunteers. In all, breath H2 concentration was measured on days 1 and 8 after ingestion of the morning lactulose dose. In four subjects, stools were collected during 2 d at the beginning and at the end of the lactulose maintenance period to measure fecal pH and daily outputs of carbohydrates and beta-galactosidase. The four other subjects were intubated on days 1 and 8 to measure the pH and the concentrations of carbohydrates, lactic acid, and volatile fatty acids (VFA) in the distal ileum and cecal contents. Moreover, 14C-lactulose was added to cold lactulose and 14CO2 breath outputs determined. Pulmonary H2 excretion fell from day 1 to day 8 (P less than 0.05), whereas 14CO2 excretion increased (P less than 0.01). Fecal water pH, lactic acid, and VFA concentrations did not vary between the two stool collection periods. 24-h fecal weight, fecal water, and carbohydrate outputs showed a trend to decrease between days 1 and 2 and days 7-8, whereas beta-galactosidase activity rose markedly (P less than 0.01). No significant variations were observed for all parameters measured in ileal fluid. In the cecum, areas under the concentration curves decreased from day 1 to day 8 for lactulose, galactose, and fructose (P less than 0.01), while an increase was found for lactic acid (P less than 0.001), acetic acid (P less than 0.0001), and total VFA (P less than 0.001). Cecal fluid pH dropped faster (P less than 0.05) and to a lower level (P less than 0.05) on day 8 than on day 1. These data clearly show that a chronic load of a nonabsorbable sugar induces changes in colonic bacterial metabolic pathways resulting in a better efficiency of the flora to digest the carbohydrate.

1 February 1999 in Gut
Verified
Journal Article
Open access
PDF file
AAA Attar
A Attar
MLM Lémann
M Lémann
AFA Ferguson
A Ferguson
MHM Halphen
M Halphen
MBM-C Boutron
M-C Boutron
MBM Barthet
M Barthet
Background Polyethylene glycol (PEG) 3350 is a non-absorbable, non-metabolised osmotic agent used in lavage solutions for gut cleansing. Aims To compare the efficacy of PEG and lactulose in chronic constipation. Methods A total of 115 patients with chronic constipation entered a multicentre, randomised, comparative trial. They initially received two sachets containing either PEG (13 g/sachet) or lactulose (10 g/sachet) and were given an option to change the dose to one or three sachets/day, depending on response. Results Ninety nine patients completed the trial. After four weeks, patients in the PEG group (n=50) had a higher number of stools and a lower median daily score for straining at stool than patients in the lactulose group (n=49). Overall improvement was greater in the PEG group. Clinical tolerance was similar in the two groups, but flatus was less frequently reported in the PEG group. The mean number of liquid stools was higher in the PEG group but the difference was significant only for the first two weeks. There were no serious adverse events and no significant change in laboratory tests in either group. At the end of the study, the number of sachets used by the patients was 1.6 (0.7)/day in the PEG group and 2.1 (0.7)/day in the lactulose group. Sixty one patients completed a further two months open study of one to three sachets PEG daily; there was no loss of efficacy and no serious toxicity. Conclusion Low dose PEG 3350 was more effective than lactulose and better tolerated.

1 September 1991 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
MLM. Lémann
M. Lémann
JDJ. P. Dederding
J. P. Dederding
BFB. Flourie
B. Flourie
CFC. Franchisseur
C. Franchisseur
JRJ. C. Rambaud
J. C. Rambaud
RJR. Jian
R. Jian